![]() | ![]() |
Formats:
|
|||||||||||||||||||||||||
Advances in the structural understanding of Vif proteins 1 LCRB, Laboratoire de cristallographie et RMN biologiques CNRS : UMR8015, Université Paris Descartes - Paris V, Faculté de Pharmacie 4 Avenue de l'Observatoire 75270 PARIS CEDEX 06,FR 2 ARN, Architecture et réactivité de l'ARN CNRS : UPR9002, Université Louis Pasteur - Strasbourg I, Institut de Biologie Moléculaire et Cellulaire 15 rue René Descartes 67084 STRASBOURG Cedex,FR * Correspondence should be adressed to: Carine Tisné Email: carine.tisne/at/univ-paris5.fr The publisher's final edited version of this article is available at Curr HIV Res. See other articles in PMC that cite the published article.Abstract The multidomain HIV-1 Vif protein recruits several cellular partners to achieve neutralization of the antiviral activity of APOBEC3 proteins. Vif neutralizes APOBEC-3G and APOBEC3F predominantly by forming an E3 ubiquitin ligase with Cullin5, ElonginB and ElonginC that targets these proteins for degradation by the ubiquitin-protea-some pathway. Vif associates with the Cullin5-ElonginB-ElonginC complex by binding directly to ElonginC via its SOCS-box motif and to Cullin5 via hydrophobic residues within a zinc-binding region formed by a conserved HCCH motif. The HIV-1 Vif-Cullin5-ElonginBC complex is then able to ubiquitinate the APOBEC3G factor bound to Vif by its N-terminal domain. In this review, we summarize the current knowledge about the structural determinants of Vif that allow it to interact with cellular and viral partners. Keywords: Amino Acid Motifs, Gene Products, vif, genetics, metabolism, HIV-1, genetics, HIV-2, genetics, Humans, Protein Binding, Protein Structure, Tertiary, Simian immunodeficiency virus, genetics Keywords: Vif protein, APOBEC3G, Cullin5, Elongin, reverse transcription, RNA I. Introduction The Human immunodeficiency virus (HIV) belongs to the Retroviridae family and, in contrast with simple retroviruses, it encodes for several proteins in addition to the three viral genes gag, pol and env, which constitute their structural and enzymatic repertoire. These proteins are usually subdivided into regulatory proteins such as Tat, Rev, and Nef, and auxiliary proteins including Vif (Virion Infectivity Factor), Vpr and Vpu. The HIV auxiliary genes, initially thought to be dispensable for viral replication, are now known to function as crucial enhancers of viral pathogenesis. Vif, Vpr and Vpu act as versatile adaptors that connect viral and cellular pathways, and lead to efficient viral replication, assembly and release (for a review, see [1]). HIV-1 Vif is a cytoplasmic, 23 kDa protein, expressed late in the viral cycle and has been known for a long time to be essential for viral replication. Vif is required in nonpermissive cells but is dispensable for replication in permissive cell lines [2–5]. In non-permissive cells, Vif-defective viruses (HIV-1Δvif) can produce virions, but they fail to complete reverse transcription and cannot successfully infect new cells [6,7]. It took almost 20 years to identify the function of Vif [8,9]. It actually counteracts the antiviral activity of recently identified members of the cellular cytidine deaminase family, APOBEC3B, APOBEC3F and APOBEC3G (for a review see [10]). In the absence of Vif, APOBEC3G is packaged into virions as a stable complex with the viral core [11,12]. This provokes the deamination of cytidine to uracil during the subsequent round of viral replication, leading to the production of non-functional proviruses. Vif interacts with and adapts APOBEC3G to an ElonginB-ElonginC-Cullin5 E3 ligase complex [13]. The bound APOBEC3G is then ubiquitinated and degraded by the proteasome, allowing viral replication. It has also been proposed that Vif can be down regulated APOBEC3G at the translational level [14–16]. Recent work suggest that DNA editing is not always necessary for antiviral activity and that APOBEC3G and APOBEC3F may exert their antiviral activity by other mechanisms than cytidine deamination [17,18]. To understand the function of a given protein at the molecular level, an appreciation of functional domains, motifs, and residues can be of tremendous help. With this aim, this review describes the general biochemical properties of Vif and then its interactions with cellular and viral partners from a structural point of view. II. General Biochemical Properties of VIF and Definition of its Different Domains To date, little structural data is available on HIV-1 Vif protein and, more importantly no three-dimensional structure exists. This lack of data is first due to the difficulty of expressing high levels of soluble recombinant protein using either prokaryotic or baculovirus expression systems. Vif is a highly basic protein (pI = 10.7) that is conserved in all lentiviruses, except Equine Infectious Anemia Virus [19]. The Vif proteins of closely related HIV-1 strains are highly conserved (e.g. 91% of identity between HIV-1 HXB2 and HIV- 1 MN isolates), while those of slightly more distantly related lentiviruses have diverged significantly (e.g. there is a maximum of 30% of identity between HIV-1 HXB2 and SIV isolates) [20]. Alignments of Vif sequences from HIV-1, HIV-2, and SIV subtypes (Fig. 1
III. The N-Terminal Domain of VIF: Interaction with APOBEC3F and APOBEC3G Seven members of the APOBEC3 family (APOBEC3A–H) have been described in primates with varying degrees of anti-viral activity, ranging from having no described activity to potent inhibitory effects against retroviruses and retrotransposons (for a review, see [10]). Binding of Vif to APOBEC3G/3F is essential for their degradation by the Vif-Cullin5 E3 ligase [9,16,42] and a detailed knowledge of the interactions between these two proteins is of great importance for the development of new drugs aiming at blocking Vif-mediated degradation of APOBEC3G. In 2004, several investigators showed that the Vif-APOBEC3G interaction is species specific [43–46]. Indeed, human, chimpanzee, rhesus macaque (mac) and African green monkey (agm) APOBEC3G proteins can inhibit Δvif HIV-1, while only the human and chimpanzee proteins are sensitive to HIV-1 Vif. Sequence analysis and mutagenesis showed that amino acid 128 (D in human and K in mac and agm) in APOBEC3G was responsible for Vif sensitivity. However, while the interaction between Vif and APOBEC3G was severely affected when amino acid 128 was mutated, it was not completely abrogated [46] and surrounding amino acids such as P129 and D130 [47] and region 54–124 [48] have been shown to modulate the APOBEC3G-Vif interaction. Unlike APOBEC3G, modification of amino acid 128 in human APOBEC3F did not change its recognition by HIV-1 or SIVagm Vif [49]. It should also be pointed out that both Vif and APOBEC3G are RNA-binding proteins [28,50] and that Vif-APOBEC3G interactions could be mediated by RNA although a recent study showed that RNA was not necessary for these proteins to interact [51]. Regarding the Vif protein, several lines of evidence suggested that the N-terminal region contains the main binding sites for APOBEC3G and APOBEC3F (Fig. 2a IV. HCCH Zn Binding Domain of VIF: a CULLIN5 Binding Domain Vif hijacks the cellular Cullin5-Ring E3 ubiquitin ligase to degrade APOBEC3 proteins (Fig. 3
V. SOCS-BOX Domain of VIF: an ELONGIN B/C Binding Domain It was known for a long time that substituting alanines for the 144SLQ149 Vif motif causes a loss of HIV-1 infectivity [66]. The molecular explanation has been discovered later [40], when this mutation was shown to affect formation of the Vif-Cullin5-ElonginBC complex. Indeed, the ElonginBElonginC heterodimer is known to interact with SOCS-box containing proteins [67,68]. Alignment of Vif proteins from primate and non primate lentiviruses led to the recognition of a highly conserved motif 144(S/T)LQ(F/Y/R)LA149 [20], homologous to a BC-box sequence conserved in proteins that bind to ElonginB-ElonginC heterodimers [69]. More recently, the conserved SLQ(Y/F)LAΦΦΦΦ motif of Vif was described to possess striking resemblance with the SOCSbox of SOCS proteins [13]. This putative SOCS-box of Vif was then shown to mediate its interaction with ElonginC [13,58]. A major difference between the SOCS-box-like motif in HIV/SIV Vif and the consensus SOCS-box motif [69] is the lack of a highly conserved C, replaced by A149 in Vif. This highly conserved C is critical for interaction with ElonginC [67]. In Vif, both A and C at position 149 can mediate the interaction with ElonginC [13]. However, longer side chain residues at this position, like L or T, prevent binding of ElonginC and degradation of APOBEC3G [13]. Amino acids 145–155 are predicted to form an α-helix (Fig. 1 To sum up, the multidomain Vif protein recruits several cellular partners to achieve the degradation of APOBEC3 proteins. Vif neutralizes the antiviral activity of APOBEC-3G and APOBEC3F predominantly by forming an E3 ubiquitin ligase with Cullin5, ElonginB and ElonginC that targets these proteins for degradation by the ubiquitin-protea-some pathway. Vif associates with the Cullin5-ElonginB-ElonginC complex by binding directly to ElonginC via its SOCS-Box motif and to Cullin5 via hydrophobic residues within a zinc-binding region formed by a conserved HCCH motif (Fig. 3 VI. Interaction with the Genomic RNA In infected cells, HIV-1 Vif co-localizes with the Pr55Gag precursor in membrane-free cytoplasmic complexes that were proposed to be intermediate assembly complexes [72]. On the other hand, Pr55Gag precursors associate with HIV-1 genomic RNA (gRNA) at a perinuclear/centrosomal site [73]. In addition, it was shown that Vif specifically binds HIV-1 gRNA in vitro, and that it binds this RNA in the cytoplasm of virus producing cells to form a 40S mRNP complex that contains neither the Pr55Gag precursor nor the mature nucleocapsid protein (NCp7) [26]. These results suggest that the HIV-1 gRNA may be engaged in different complexes. However, the same authors showed that in vitro, the affinity of Vif for the HIV-1 gRNA significantly decreased in the presence of Pr55Gag, while the affinity of the latter protein for HIV-1 RNA was not affected by Vif. Recently, we found that Vif preferentially and cooperatively binds to the 5′ region of the HIV-1 gRNA, and that this region contains very high affinity Vif binding sites [28,74]. Therefore, one can assume that some Vif proteins would remain associated to the gRNA even in the presence of Gag. Indeed, by studying the cell-free assembly of immature HIV-1 capsids, Lingappa and co-workers observed intermediate assembly complexes containing the Gag and Gag-Pol precursors, as well as Vif and a cellular factor, HP68, which is absolutely required to complete assembly [75]. In line with these results, it has been reported that incorporation of Vif into viral particles is mediated (at least in part) by interactions with the gRNA [27]. Interactions of Vif with Gag and Gag-Pol likely also contribute to this process [76]. A strong affinity RNA binding site was identified in the N-terminal region of Vif (amino acids 1–64), while the Cterminal region, which harbors many positively charged residues, only weakly contributed to RNA binding [26]. Within the N-terminal region of Vif, substitutions W11A, Y30A, and Y40A strongly reduced binding to both poly(G) and an RNA probe corresponding to nucleotides 5104 to 5287 of the HIV-1 genome. In addition, viruses harboring any of these substitutions were non-infectious in H9 T cells, suggesting that RNA binding is crucial for Vif function [26]. Moreover, viruses harboring mutations in the zinc finger domains of NCp7 that fail to package gRNA do not package Vif, and Vif is not encapsidated in a HIV-1 RNA-packaging mutant [27]. These authors also showed that deletions of the C-terminal domain or of the viral SOCS-box had no effect on Vif packaging. Surprisingly in light of the results of Zhang et al. mentioned above, Khan and co-workers found that deletion of residues 23 to 43 increased the efficiency of Vif packaging twofold [27]. On the other hand, deletion of amino acids 75 to 114 completely abolished packaging of Vif. However, as this deletion encompasses part of the zincbinding motif (Fig. 2b The main HIV-1 RNA binding protein is the mature nucleocapsid protein NCp7 (and the NC domain embedded in the Gag precursor), which is a potent RNA chaperone (For reviews see [77,78]). Recent studies pointed at significant differences and similarities between Vif and NCp7. Whereas the binding affinity of NCp7 for RNA strongly decreases as the salt concentration increases [77,79], the Vif/RNA complexes resist to high salt concentrations [26,28,74]. Indeed, at the physiological ionic conditions, Vif binds stronger to gRNA than NCp7 [28,74]. NCp7 binds to any nucleic acids with significant affinity, but it displays some preference for UG or TG-rich sequences and for GNG sequences within single stranded loops. The RNA and DNA sites displaying the highest affinity for Vif are single-stranded G-rich and Crich sequences [74] and poly(G) is the homopolymer that binds Vif with the highest affinity [26]. The determinants of specific binding of Vif to nucleic acids remain to be determined, but Vif binding seems to be more specific than NCp7 binding, as we identified 500 nucleotide RNA fragments that weakly bind Vif [28,74]. Interestingly, we recently found that Vif promotes annealing of tRNALys,3 to the primer binding site (PBS), favors dimerization of the HIV-1 gRNA, decreases pausing of reverse transcriptase and enhances the first strand transfer taking place during reverse transcription, indicating that Vif is a bona fide RNA chaperone [80]. Even though the chaperone activity of Vif is less pronounced than that of NCp7, Vif has dominant effects on NCp7. Indeed, Vif inhibits some, but not all, NCp7-mediated functions including tRNALys,3 annealing and conversion of the loose gRNA dimer into a tight dimer [80]. These inhibitory effects of Vif are likely relieved at the last stages of virion assembly, as only limited amounts of Vif are packaged [81–84], and thus Vif could act as a temporal regulator of NCp7 activity. Recent reports indicated that deamination is only one of the mechanisms contributing to the antiviral activity of APOBEC3G and APOBEC3F. Some authors reported that these proteins also inhibit NCp7- mediated tRNALys,3 annealing [85], and DNA strand transfers during reverse transcription [86], while others observed an effect on DNA elongation [87]. These results may explain the need for redundant RNA chaperone activities in cells expressing APOBEC3G and APOBEC3F. CONCLUSIONS In conclusion, Vif is a multidomain and multifunctional protein that therefore represent a viable target for both therapeutic and preventive interventions. However, there are currently no drugs against this protein in clinical trials. To date, its function and structural features have been fairly well investigated. However, there still exist numerous aspects that need to be resolved. A three-dimensional structure of Vif, alone if Vif is not intrinsically disordered, or in complex with cellular partner(s) would greatly help us to understand its behavior at the molecular level. Acknowledgments JCP and RM wish to thank Simon Henriet, Gaelle Mercenne, Serena Bernacchi, and Lucile Sinck who participated in the work performed in the Marquet’s Lab described in this review. The authors thank the ‘Agence Nationale de Recherche sur le SIDA’ (ANRS) and the CNRS for financial support in their respective laboratories. ABBREVIATIONS
References 1. Strebel K. HIV accessory genes Vif and Vpu. Adv Pharmacol. 2007;55:199–232. [PubMed] 2. Fan L, Peden K. Cell-free transmission of Vif mutants of HIV-1. Virology. 1992;190:19–29. [PubMed] 3. Gabuzda DH, Lawrence K, Langhoff E, et al. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol. 1992;66:6489–6495. [PubMed] 4. Borman AM, Quillent C, Charneau P, Dauguet C, Clavel F. Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol. 1995;69:2058–2067. [PubMed] 5. Courcoul M, Patience C, Rey F, et al. Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol. 1995;69:2068–2074. [PubMed] 6. Sova P, Volsky DJ. Efficiency of viral DNA synthesis during infection of permissive and non-permissive cells with vif-negative human immunodeficiency virus type 1. J Virol. 1993;67:6322–6326. [PubMed] 7. von Schwedler U, Song J, Aiken C, Trono D. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol. 1993;67:4945–4955. [PubMed] 8. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418:646–650. [PubMed] 9. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med. 2003;9:1398–1403. [PubMed] 10. Holmes RK, Malim MH, Bishop KN. APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci. 2007;32:118–128. [PubMed] 11. Khan MA, Kao S, Miyagi E, et al. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol. 2005;79:5870–5874. [PubMed] 12. Soros VB, Yonemoto W, Greene WC. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 2007;3:e15. [PubMed] 13. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 2004;18:2867–2872. [PubMed] 14. Kao S, Khan MA, Miyagi E, et al. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol. 2003;77:11398–11407. [PubMed] 15. Mariani R, Chen D, Schrofelbauer B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 2003;114:21–31. [PubMed] 16. Stopak K, de Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell. 2003;12:591–601. [PubMed] 17. Newman EN, Holmes RK, Craig HM, et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol. 2005;15:166–170. [PubMed] 18. Holmes RK, Koning FA, Bishop KN, Malim MH. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem. 2007;282:2587–2595. [PubMed] 19. Kawakami T, Sherman L, Dahlberg J, et al. Nucleotide sequence analysis of equine infectious anemia virus proviral DNA. Virology. 1987;158:300–312. [PubMed] 20. Oberste MS, Gonda MA. Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes. 1992;6:95–102. [PubMed] 21. Tian C, Yu X, Zhang W, et al. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol. 2006;80:3112–3115. [PubMed] 22. Fujita M, Akari H, Sakurai A, et al. Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect. 2004;6:791–798. [PubMed] 23. Xiao Z, Ehrlich E, Yu Y, et al. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology. 2006;349:290–299. [PubMed] 24. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem. 2006;281:17259–17265. [PubMed] 25. Dettenhofer M, Cen S, Carlson BA, Kleiman L, Yu XF. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol. 2000;74:8938–8945. [PubMed] 26. Zhang H, Pomerantz RJ, Dornadula G, Sun Y. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol. 2000;74:8252–8261. [PubMed] 27. Khan MA, Aberham C, Kao S, et al. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol. 2001;75:7252–7265. [PubMed] 28. Henriet S, Richer D, Bernacchi S, et al. Cooperative and specific binding of Vif to the 5′ region of HIV-1 genomic RNA. J Mol Biol. 2005;354:55–72. [PubMed] 29. Khan MA, Akari H, Kao S, et al. Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. J Virol. 2002;76:9112–9123. [PubMed] 30. Hutoran M, Britan E, Baraz L, et al. Abrogation of Vif function by peptide derived from the N-terminal region of the human immunodeficiency virus type 1 (HIV-1) protease. Virology. 2004;330:261–270. [PubMed] 31. Yang X, Goncalves J, Gabuzda D. Phosphorylation of Vif and its role in HIV-1 replication. J Biol Chem. 1996;271:10121–10129. [PubMed] 32. Yang X, Gabuzda D. Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein. J Biol Chem. 1998;273:29879–29887. [PubMed] 33. Yang S, Sun Y, Zhang H. The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J Biol Chem. 2001;276:4889–4893. [PubMed] 34. Auclair JR, Green KM, Shandilya S, et al. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins. 2007;69:270–284. [PubMed] 35. Yang B, Gao L, Li L, et al. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J Biol Chem. 2003;278:6596–6602. [PubMed] 36. Miller JH, Presnyak V, Smith HC. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block APOBEC3G incorporation with virions. Retrovirology. 2007;4:81. [PubMed] 37. Balaji S, Kalpana R, Shapshak P. Paradigm development: comparative and predictive 3D modeling of HIV-1 Virion Infectivity Factor (Vif). Bioinformation. 2006;1:290–309. [PubMed] 38. Lv W, Liu Z, Jin H, et al. Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. Org Biomol Chem. 2007;5:617–626. [PubMed] 39. Liu B, Yu X, Luo K, Yu Y, Yu XF. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol. 2004;78:2072–2081. [PubMed] 40. Yu X, Yu Y, Liu B, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 2003;302:1056–1060. [PubMed] 41. Mehle A, Strack B, Ancuta P, et al. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem. 2004;279:7792–7798. [PubMed] 42. Conticello SG, Harris RS, Neuberger MS. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol. 2003;13:2009–2013. [PubMed] 43. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA. 2004;101:3770–3774. [PubMed] 44. Mangeat B, Turelli P, Liao S, Trono D. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem. 2004;279:14481–14483. [PubMed] 45. Schrofelbauer B, Chen D, Landau NR. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA. 2004;101:3927–3932. [PubMed] 46. Xu H, Svarovskaia ES, Barr R, et al. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci USA. 2004;101:5652–5657. [PubMed] 47. Huthoff H, Malim MH. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol. 2007;81:3807–3815. [PubMed] 48. Li J, Potash MJ, Volsky DJ. Functional domains of APOBEC3G required for antiviral activity. J Cell Biochem. 2004;92:560–572. [PubMed] 49. Liu B, Sarkis PT, Luo K, Yu Y, Yu XF. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5- ElonB/C E3 ubiquitin ligase. J Virol. 2005;79:9579–9587. [PubMed] 50. Iwatani Y, Takeuchi H, Strebel K, Levin JG. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol. 2006;80:5992–6002. [PubMed] 51. Gallois-Montbrun S, Kramer B, Swanson CM, et al. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol. 2007;81:2165–2178. [PubMed] 52. Simon V, Zennou V, Murray D, et al. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV- 1 diversification. PLoS Pathog. 2005;1:e6. [PubMed] 53. Santa-Marta M, Aires da Silva F, Fonseca A, Goncalves J. HIV-1 Vif can directly inhibit APOBEC3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J Biol Chem. 2005;280:8765–8775. [PubMed] 54. Wichroski MJ, Ichiyama K, Rana TM. Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J Biol Chem. 2005;280:8387–8396. [PubMed] 55. Schrofelbauer B, Senger T, Manning G, Landau NR. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol. 2006;80:5984–5991. [PubMed] 56. Mehle A, Wilson H, Zhang C, et al. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol. 2007;81:13235–13241. [PubMed] 57. Russell RA, Pathak VK. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol. 2007;81:8201–8210. [PubMed] 58. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 2004;18:2861–2866. [PubMed] 59. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol. 1999;15:435–467. [PubMed] 60. Pintard L, Willems A, Peter M. Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family. EMBO J. 2004;23:1681–1687. [PubMed] 61. Xiao Z, Xiong Y, Zhang W, et al. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J Mol Biol. 2007;373:541–550. [PubMed] 62. Luo K, Xiao Z, Ehrlich E, et al. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci USA. 2005;102:11444–11449. [PubMed] 63. Krishna SS, Majumdar I, Grishin NV. Structural classification of zinc fingers: survey and summary. Nucleic Acids Res. 2003;31:532–550. [PubMed] 64. Paul I, Cui J, Maynard EL. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci USA. 2006;103:18475–18480. [PubMed] 65. Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu XF. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 2007;21:217–222. [PubMed] 66. Simon JH, Sheehy AM, Carpenter EA, Fouchier RA, Malim MH. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J Virol. 1999;73:2675–2681. [PubMed] 67. Kamura T, Sato S, Haque D, et al. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 1998;12:3872–3881. [PubMed] 68. Zhang JG, Farley A, Nicholson SE, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA. 1999;96:2071–2076. [PubMed] 69. Kile BT, Schulman BA, Alexander WS, et al. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci. 2002;27:235–241. [PubMed] 70. Stebbins CE, Kaelin WG, Jr, Pavletich NP. Structure of the VHLElonginC- ElonginB complex: implications for VHL tumor suppressor function. Science. 1999;284:455–461. [PubMed] 71. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J Biol Chem. 2005;280:18573–18578. [PubMed] 72. Simon JH, Carpenter EA, Fouchier RA, Malim MH. Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol. 1999;73:2667–2674. [PubMed] 73. Poole E, Strappe P, Mok HP, Hicks R, Lever AM. HIV-1 Gag- RNA interaction occurs at a perinuclear/centrosomal site; analysis by confocal microscopy and FRET. Traffic. 2005;6:741–755. [PubMed] 74. Bernacchi S, Henriet S, Dumas P, Paillart JC, Marquet R. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study. J Biol Chem. 2007;282:26361–26368. [PubMed] 75. Zimmerman C, Klein KC, Kiser PK, et al. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature. 2002;415:88–92. [PubMed] 76. Bardy M, Gay B, Pebernard S, et al. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: coencapsidation and interference with viral protease-mediated Gag processing. J Gen Virol. 2001;82:2719–2733. [PubMed] 77. Levin JG, Guo J, Rouzina I, Musier-Forsyth K. Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse transcription and molecular mechanism. Prog Nucleic Acid Res Mol Biol. 2005;80:217–286. [PubMed] 78. Tisne C. Structural bases of the annealing of primer tRNA(3Lys) to the HIV-1 viral RNA. Curr HIV Res. 2005;3:147–156. [PubMed] 79. Barraud P, Gaudin C, Dardel F, Tisne C. New insights into the formation of HIV-1 reverse transcription initiation complex. Biochimie. 2007;89:1204–1210. [PubMed] 80. Henriet S, Sinck L, Bec G, et al. Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res. 2007;35:5141–5153. [PubMed] 81. Liu H, Wu X, Newman M, et al. The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J Virol. 1995;69:7630–7638. [PubMed] 82. Camaur D, Trono D. Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol. 1996;70:6106–6111. [PubMed] 83. Dettenhofer M, Yu XF. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J Virol. 1999;73:1460–1467. [PubMed] 84. Kao S, Akari H, Khan MA, et al. Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol. 2003;77:1131–1140. [PubMed] 85. Guo F, Cen S, Niu M, et al. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J Virol. 2007;81:11322–11331. [PubMed] 86. Li XY, Guo F, Zhang L, Kleiman L, Cen S. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J Biol Chem. 2007;282:32065–32074. [PubMed] 87. Iwatani Y, Chan DS, Wang F, et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 2007 88. Jones DT. Protein secondary structure prediction based on positionspecific scoring matrices. J Mol Biol. 1999;292:195–202. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
||||||||||||||||||||||||
Adv Pharmacol. 2007; 55():199-232.
[Adv Pharmacol. 2007]Virology. 1992 Sep; 190(1):19-29.
[Virology. 1992]J Virol. 1995 Apr; 69(4):2068-74.
[J Virol. 1995]J Virol. 1993 Oct; 67(10):6322-6.
[J Virol. 1993]J Virol. 1993 Aug; 67(8):4945-55.
[J Virol. 1993]Curr Biol. 2005 Jan 26; 15(2):166-70.
[Curr Biol. 2005]J Biol Chem. 2007 Jan 26; 282(4):2587-95.
[J Biol Chem. 2007]Virology. 1987 Jun; 158(2):300-12.
[Virology. 1987]Virus Genes. 1992 Jan; 6(1):95-102.
[Virus Genes. 1992]J Virol. 2006 Mar; 80(6):3112-5.
[J Virol. 2006]Microbes Infect. 2004 Jul; 6(9):791-8.
[Microbes Infect. 2004]Virology. 2006 Jun 5; 349(2):290-9.
[Virology. 2006]Trends Biochem Sci. 2007 Mar; 32(3):118-28.
[Trends Biochem Sci. 2007]Nat Med. 2003 Nov; 9(11):1398-403.
[Nat Med. 2003]Mol Cell. 2003 Sep; 12(3):591-601.
[Mol Cell. 2003]Curr Biol. 2003 Nov 11; 13(22):2009-13.
[Curr Biol. 2003]Proc Natl Acad Sci U S A. 2004 Mar 16; 101(11):3770-4.
[Proc Natl Acad Sci U S A. 2004]Nat Med. 2003 Nov; 9(11):1398-403.
[Nat Med. 2003]J Virol. 2006 Mar; 80(6):3112-5.
[J Virol. 2006]Curr Biol. 2003 Nov 11; 13(22):2009-13.
[Curr Biol. 2003]PLoS Pathog. 2005 Sep; 1(1):e6.
[PLoS Pathog. 2005]J Virol. 2007 Aug; 81(15):8201-10.
[J Virol. 2007]Genes Dev. 2004 Dec 1; 18(23):2867-72.
[Genes Dev. 2004]Science. 2003 Nov 7; 302(5647):1056-60.
[Science. 2003]Genes Dev. 2004 Dec 1; 18(23):2861-6.
[Genes Dev. 2004]Annu Rev Cell Dev Biol. 1999; 15():435-67.
[Annu Rev Cell Dev Biol. 1999]EMBO J. 2004 Apr 21; 23(8):1681-7.
[EMBO J. 2004]J Virol. 1999 Apr; 73(4):2675-81.
[J Virol. 1999]Science. 2003 Nov 7; 302(5647):1056-60.
[Science. 2003]Genes Dev. 1998 Dec 15; 12(24):3872-81.
[Genes Dev. 1998]Proc Natl Acad Sci U S A. 1999 Mar 2; 96(5):2071-6.
[Proc Natl Acad Sci U S A. 1999]Virus Genes. 1992 Jan; 6(1):95-102.
[Virus Genes. 1992]Science. 1999 Apr 16; 284(5413):455-61.
[Science. 1999]Genes Dev. 2004 Dec 1; 18(23):2867-72.
[Genes Dev. 2004]J Biol Chem. 2005 May 13; 280(19):18573-8.
[J Biol Chem. 2005]J Virol. 1999 Apr; 73(4):2667-74.
[J Virol. 1999]Traffic. 2005 Sep; 6(9):741-55.
[Traffic. 2005]J Virol. 2000 Sep; 74(18):8252-61.
[J Virol. 2000]J Mol Biol. 2005 Nov 18; 354(1):55-72.
[J Mol Biol. 2005]J Biol Chem. 2007 Sep 7; 282(36):26361-8.
[J Biol Chem. 2007]J Virol. 2000 Sep; 74(18):8252-61.
[J Virol. 2000]J Virol. 2001 Aug; 75(16):7252-65.
[J Virol. 2001]Prog Nucleic Acid Res Mol Biol. 2005; 80():217-86.
[Prog Nucleic Acid Res Mol Biol. 2005]Curr HIV Res. 2005 Apr; 3(2):147-56.
[Curr HIV Res. 2005]Biochimie. 2007 Oct; 89(10):1204-10.
[Biochimie. 2007]J Virol. 2000 Sep; 74(18):8252-61.
[J Virol. 2000]J Mol Biol. 2005 Nov 18; 354(1):55-72.
[J Mol Biol. 2005]Nucleic Acids Res. 2007; 35(15):5141-53.
[Nucleic Acids Res. 2007]J Virol. 1995 Dec; 69(12):7630-8.
[J Virol. 1995]J Virol. 2003 Jan; 77(2):1131-40.
[J Virol. 2003]J Virol. 2007 Oct; 81(20):11322-31.
[J Virol. 2007]J Biol Chem. 2007 Nov 2; 282(44):32065-74.
[J Biol Chem. 2007]J Mol Biol. 1999 Sep 17; 292(2):195-202.
[J Mol Biol. 1999]